OBJECTIVE: To compare plasma concentrations of soluble P-selectin (sP-selectin) in patients with rheumatoid arthritis (RA) and thrombocytosis with those with RA with normal platelet counts and healthy controls, and to explore the relationship between clinical and serological measures of disease activity. METHODS: Nineteen patients with RA with marked thrombocytosis, 20 with normal platelet counts, and 24 controls were enrolled. Ritchie articular index and morning stiffness were recorded as clinical markers of disease activity. Blood samples were collected for platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and plasma sP-selectin determinations. Correlations between sP-selectin and clinical and serological markers of disease activity were noted. RESULTS: Patients with RA and thrombocytosis compared to patients with normal platelet counts showed evidence of more active disease when ESR, CRP, morning stiffness, and Ritchie articular index were considered. The thrombocyte count in patients with RA with marked thrombocytosis revealed a positive correlation with CRP and Ritchie articular score. Plasma sP-selectin levels were found to be significantly higher in patients with RA compared to controls. sP-selectin levels were significantly higher in patients with RA with thrombocytosis compared to those with normal platelet counts, and positive correlations were observed between plasma sP-selectin levels and Ritchie index, morning stiffness, and thrombocyte counts in those patients. CONCLUSION: Elevated plasma sP-selectin levels in RA could indicate the presence of a continuous underlying inflammatory stimulus. In addition, the augmented increase in patients with RA and thrombocytosis and its correlation with clinical activity may imply the cytokine-adhesion molecule interaction mediates the chronic inflammation of RA.
OBJECTIVE: To compare plasma concentrations of soluble P-selectin (sP-selectin) in patients with rheumatoid arthritis (RA) and thrombocytosis with those with RA with normal platelet counts and healthy controls, and to explore the relationship between clinical and serological measures of disease activity. METHODS: Nineteen patients with RA with marked thrombocytosis, 20 with normal platelet counts, and 24 controls were enrolled. Ritchie articular index and morning stiffness were recorded as clinical markers of disease activity. Blood samples were collected for platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and plasma sP-selectin determinations. Correlations between sP-selectin and clinical and serological markers of disease activity were noted. RESULTS:Patients with RA and thrombocytosis compared to patients with normal platelet counts showed evidence of more active disease when ESR, CRP, morning stiffness, and Ritchie articular index were considered. The thrombocyte count in patients with RA with marked thrombocytosis revealed a positive correlation with CRP and Ritchie articular score. Plasma sP-selectin levels were found to be significantly higher in patients with RA compared to controls. sP-selectin levels were significantly higher in patients with RA with thrombocytosis compared to those with normal platelet counts, and positive correlations were observed between plasma sP-selectin levels and Ritchie index, morning stiffness, and thrombocyte counts in those patients. CONCLUSION: Elevated plasma sP-selectin levels in RA could indicate the presence of a continuous underlying inflammatory stimulus. In addition, the augmented increase in patients with RA and thrombocytosis and its correlation with clinical activity may imply the cytokine-adhesion molecule interaction mediates the chronic inflammation of RA.
Authors: Armen Yuri Gasparyan; Antonios Stavropoulos-Kalinoglou; Dimitri P Mikhailidis; Karen M J Douglas; George D Kitas Journal: Rheumatol Int Date: 2011-02 Impact factor: 2.631
Authors: Monique Bethel; Calvin L T Barnes; Amanda F Taylor; Ying-Hua Cheng; Brahmananda R Chitteti; Mark C Horowitz; Angela Bruzzaniti; Edward F Srour; Melissa A Kacena Journal: J Cell Physiol Date: 2015-09 Impact factor: 6.384
Authors: Jana Burkhardt; Mechthild Blume; Elisabeth Petit-Teixeira; Vitor Hugo Teixeira; Anke Steiner; Elfi Quente; Grit Wolfram; Markus Scholz; Céline Pierlot; Paola Migliorini; Stefano Bombardieri; Alejandro Balsa; René Westhovens; Pilar Barrera; Timothy R D J Radstake; Helena Alves; Thomas Bardin; Bernard Prum; Frank Emmrich; François Cornelis; Peter Ahnert; Holger Kirsten Journal: PLoS One Date: 2014-08-22 Impact factor: 3.240
Authors: John R Stack; Anne Madigan; Laura Helbert; Eimear Dunne; Elizabeth E Gardiner; Robert K Andrews; Roisin Finan; Elizabeth Smyth; Dermot Kenny; Geraldine M McCarthy Journal: PLoS One Date: 2017-11-15 Impact factor: 3.240
Authors: Su Jeong Lee; Bo Ruem Yoon; Hee Young Kim; Su-Jin Yoo; Seong Wook Kang; Won-Woo Lee Journal: Front Immunol Date: 2021-01-07 Impact factor: 7.561
Authors: Kim L L Habets; Leendert A Trouw; E W Nivine Levarht; Suzanne J A Korporaal; Petra A M Habets; Philip de Groot; Tom W J Huizinga; René E M Toes Journal: Arthritis Res Ther Date: 2015-08-24 Impact factor: 5.156